Pricing Log in Create free account

Dermata Therapeutics, Inc. (DRMA) vs Longeveron Inc. (LGVN)

Dermata Therapeutics, Inc. and Longeveron Inc. are both Biotechnology companies. Dermata Therapeutics, Inc. and Longeveron Inc. are of similar size ($4.8M and $4.5M). Dermata Therapeutics, Inc. has the higher net margin (0.00% vs −1,977.6%) and the higher return on invested capital (0.00% vs −4,549.0%). Across the 13 metrics below, Dermata Therapeutics, Inc. leads on 11 and Longeveron Inc. on 2.

Valuation

Metric DRMA LGVN Biotechnology median
P/E n/m n/m 8.50
P/S n/m 3.67 9.71
P/B 0.99 0.42 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.03 0.22 0.64
EV/Sales n/m (4.16) 9.21
Earnings yield (510.47%) (712.23%) (33.15%)
Free cash flow yield (232.27%) (477.81%) (25.50%)

Profitability

Metric DRMA LGVN Biotechnology median
Gross margin — 69.76% 65.16%
Operating margin 0.00% (1,992.84%) 0.00%
Net margin 0.00% (1,977.59%) 0.00%
Free cash flow margin 0.00% (1,755.69%) 0.00%
Return on equity (183.89%) (203.61%) (56.36%)
Return on assets (139.93%) (145.64%) (48.04%)
Return on invested capital 0.00% (4,549.04%) 0.00%

Growth

Metric DRMA LGVN Biotechnology median
Revenue growth (TTM) — (42.74%) 6.02%
EPS growth (last fiscal year) 89.84% 50.76% 30.26%
Revenue growth, 5-year CAGR — (26.60%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DRMA LGVN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.81 2.63 4.72
Net debt to EBITDA 0.97 0.20 0.96

Dividend

Metric DRMA LGVN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DRMA LGVN Biotechnology median
Market cap 4.51m 4.79m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack